Blog
RSS FeedPosted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 20 May 2019
UCB announces Nayzilam (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the US
19 May 2019 - Nayzilam allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure ...
Posted by Michael Wonder on 18 May 2019
U.S. FDA approves Gattex (teduglutide) for children 1 year of age and older with short bowel syndrome
17 May 2019 - Gattex is the only glucagon-like peptide-2 analogue approved that improves intestinal absorption in patients with SBS who ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 17 May 2019
Celgene receives European Commission approvals for Revlimid (lenalidomide) and Imnovid (pomalidomide)-based triplet combination regimens for patients with multiple myeloma
16 May 2019 - The European Commission has approved two of Celgene’s IMiD based combination regimens. ...
Posted by Michael Wonder on 17 May 2019
Health Canada approves injectable hydromorphone to treat opioid addiction
16 May 2019 - Canada is first country to approve the pain drug for severe opioid use disorder, says Health ...
Posted by Michael Wonder on 16 May 2019
FDA approves first anticoagulant (blood thinner) for paediatric patients to treat potentially life-threatening blood clots
16 May 2019 - The U.S. FDA today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 15 May 2019
Novartis gets approval to sell Kymriah in Japan for $306,000
15 May 2019 - A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer ...
Posted by Michael Wonder on 15 May 2019
AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukaemia patients
15 May 2019 - FDA reviewed the submission under the real-time oncology review pilot program. ...
Posted by Michael Wonder on 15 May 2019
NICE recommends first ever treatment for children with rare muscle wasting condition
15 May 2019 - Children with the rare genetic disorder spinal muscular atrophy can now be treated with nusinersen after NICE ...
Posted by Michael Wonder on 15 May 2019
FDA approves Bavencio (avelumab) plus axitinib combination for patients with advanced renal cell carcinoma
14 May 2019 - Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended ...
Posted by Michael Wonder on 14 May 2019
FDA approves Eylea (aflibercept) injection for diabetic retinopathy
13 May 2019 - Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. ...
Posted by Michael Wonder on 14 May 2019
FDA approves broadened indication for Xeomin (incobotulinumtoxinA) as first-line treatment for blepharospasm (involuntary blinking) in adult patients
13 May 2019 - Merz Americas announced today that the U.S. FDA has approved the supplemental biologics license application for Xeomin ...
Posted by Michael Wonder on 13 May 2019
New cancer drugs approved for NHS use in Scotland
13 May 2019 - The Scottish Medicines Consortium accepted the use of new medicines to treat patients with breast and skin ...